Hyperinsulinemia and Atherosclerosis
The DOI matches its Crossref record.
Abstract
For more than 25 years, there has been an expansion in the clinical and experimental evidence linking hyperinsulinemia with cardiovascular disease and atherosclerosis. Assessment of the evidence under the headings of the strength of the association, dose response, temporality, consistency, specificity, and plausibility supports the concept that hyperinsulinemia has a causal role in atherogenesis. Evidence that reducing insulin levels prevents atherosclerosis is lacking. The evidence available is strong enough to support preventive measures to lower insulin levels such as regular physical exercise and avoidance of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475
Kawano, H., Motoyama, T., Hirashima, O., Hirai, N., Miyao, Y., Sakamoto, T., Kugiyama, K., Ogawa, H., & Yasue, H. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00168-0 · Cited by 676
Closed-loop insulin delivery—the path to physiological glucose control
Steil, G. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.08.011 · Cited by 313
Janssen, J. A. M. J. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157797 · Cited by 294
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Early Insulin Use in Type 2 Diabetes
Chiasson, J.-L. (2009) · Diabetes Care · doi:10.2337/dc09-s321 · Cited by 24
Metadata
- Authors
- Stout, R. W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1996-07-01
- Volume
- 45
- Issue
- Supplement_3
- Pages
- S45-S46
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2124457064
- Cited by
- 96
- References
- 0
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.